1,3-Benzodioxolyl-N-methylpentanamine

MBDP
Clinical data
Other names1,3-Benzodioxolyl-N-methylpentanamine; N-Methyl-1,3-benzodioxolylpentanamine; MBDP; 3,4-Methylenedioxy-α-propyl-N-methylphenethylamine; Methyl-K; UWA-091; UWA091
Routes of
administration		Oral
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown
Identifiers
  • 1-(2H-1,3-benzodioxol-5-yl)-N-methylpentan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H19NO2
Molar mass221.300 g·mol−1
3D model (JSmol)
  • C1=C2C(=CC=C1CC(NC)CCC)OCO2
  • InChI=1S/C13H19NO2/c1-3-4-11(14-2)7-10-5-6-12-13(8-10)16-9-15-12/h5-6,8,11,14H,3-4,7,9H2,1-2H3
  • Key:PZVRSDBLMSXDCX-UHFFFAOYSA-N

MBDP, also known as N-methyl-1,3-benzodioxolylpentanamine, 3,4-methylenedioxy-α-propyl-N-methylphenethylamine, methyl-K, or UWA-091, is a psychoactive drug of the phenethylamine, phenylisobutylamine, and MDxx families. It is the N-methyl analogue of BDP (K).

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MBDP's minimum dose as 100 mg orally and its duration as unknown. The drug produced no effects at tested doses.

Chemistry

Synthesis

The chemical synthesis of MBDP has been described.

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.

See also

References

  1. 1 2 3 4 5 6 7 "Methyl-K". PiHKAL.
  2. ↑ Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
  3. ↑ Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.
  4. ↑ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.